Pancreatic Pathology — Pancreatitis and Carcinoma

Acute Pancreatitis Mechanisms

Premature enzyme activation within acinar cells

• Under normal conditions, digestive enzymes (amylase, lipase, proteases) are stored as inactive zymogens in acinar cell secretory granules
• Pancreatic injury triggers aberrant colocalization of lysosomal hydrolases (cathepsin B) with zymogen granules, leading to premature protease activation within cells
• Activated proteases autodigest pancreatic parenchyma, causing acute inflammation, acinar cell necrosis, and edema

Inflammatory cascade amplification

• Acinar cell injury releases damage-associated molecular patterns (DAMPs) and inflammatory mediators (TNF-α, IL-6, IL-8)
• Nuclear factor-kappa B (NF-κB) activation in acinar cells and resident macrophages amplifies chemokine production
• Massive influx of neutrophils and macrophages causes acute necrotizing inflammation, contributing to systemic inflammatory response syndrome (SIRS)

Vascular injury and microcirculatory dysfunction

• Inflammatory mediators increase vascular permeability and cause interstitial edema (edematous pancreatitis)
• Severe cases progress to hemorrhagic pancreatitis with vascular injury, thrombosis, and acinar necrosis
• Pancreatic necrosis can become secondarily infected, leading to infected pancreatic necrosis

Chronic Pancreatitis Mechanisms

Oxidative stress and stellate cell activation

• Recurrent or persistent pancreatic injury generates reactive oxygen species (ROS) and oxidative stress
• Pancreatic stellate cells (myofibroblasts) are activated by inflammatory cytokines (TGF-β, TNF-α) and oxidative stress
• Activated stellate cells proliferate and undergo fibrosis, producing excessive collagen deposition (types I and III)

Protein precipitation and ductal obstruction

• Chronic alcohol exposure causes hypersecretion of pancreatic juice with increased protein concentration
• Abnormal proteins precipitate within small ducts, forming protein plugs and concretions
• Progressive ductal obstruction increases intraductal pressure, causing atrophy of acini while ducts dilate

Parenchymal atrophy and fibrosis

• Combination of repeated inflammation, oxidative stress, and ductal obstruction leads to irreversible loss of acinar tissue
• Progressive fibrosis replaces destroyed parenchyma; fatty infiltration occurs in advanced disease
• Islet cells (endocrine pancreas) are relatively preserved early but gradually decline, potentially leading to secondary diabetes mellitus

Pancreatic Ductal Adenocarcinoma Mechanisms

Sequential genetic alterations (PDAC progression model)

• KRAS mutations (~90%): Occur early, often in normal-appearing pancreatic ducts; lead to constitutive MAPK/ERK pathway activation and uncontrolled proliferation
• TP53 mutations (~50-70%): Loss of p53 tumor suppressor function eliminates G1/S checkpoint and apoptosis
• CDKN2A/p16 loss (~95%): Inactivation of cell cycle inhibitor accelerates progression through G1/S phase
• SMAD4/DPC4 loss (~55%): Disruption of TGF-β signaling pathway eliminates growth-inhibitory signals
• BRCA1/BRCA2 mutations (~5-10%): Impaired DNA repair increases genomic instability

Precursor lesions (adenoma-carcinoma sequence)

• Pancreatic intraepithelial neoplasia (PanIN): Low-grade (PanIN-1) → Intermediate (PanIN-2) → High-grade (PanIN-3) dysplasia; found in ~40% of chronic pancreatitis cases and most PDAC specimens
• Intraductal papillary mucinous neoplasms (IPMN): Mucinous tumors arising from main or branch ducts; variable malignant potential (20-90% depending on type and grade)
• Mucinous cystic neoplasms (MCN): Occur predominantly in women; 60-90% malignant transformation rate

Microenvironment and stromal desmoplasia

• Dense desmoplastic fibrotic stroma surrounds tumor cells, accounting for 80-90% of tumor volume
• Stromal fibroblasts produce collagen and extracellular matrix, promoting immune evasion and limiting drug penetration
• Pancreatic stellate cells, activated by TGF-β and other cytokines, contribute to this tumor-promoting microenvironment

Epithelial-mesenchymal transition (EMT) and metastatic potential

• Downregulation of E-cadherin and upregulation of N-cadherin reduce cell-cell adhesion
• Expression of transcription factors (Snail, Slug, Twist) promotes acquisition of mesenchymal phenotype
• EMT enhances invasiveness, intravasation, and early metastatic dissemination

Acute Pancreatitis

Biliary obstruction (40-50% of AP cases)

• Gallstones are the single most common cause in Western populations, particularly small stones <5 mm that can pass into ampulla of Vater
• Transient pancreatic duct obstruction at sphincter of Oddi raises intraductal pressure, triggering acinar injury
• Risk increases with female sex, age >40, obesity, and estrogen use (FAT mnemonic: Female, Age, Triglycerides)

Alcohol consumption (30-40% of AP cases)

• Direct toxicity to acinar cells with generation of toxic metabolites (acetaldehyde, fatty acid ethyl esters)
• Triggers stellate cell activation and oxidative stress even before chronic pancreatitis develops
• Binge drinking or chronic heavy consumption both implicated; threshold-dependent effect

Hypertriglyceridemia (1-10% of AP cases)

• Severe hypertriglyceridemia (typically >1000 mg/dL, usually >10 mmol/L) is independent risk factor
• Mechanism incompletely understood; may involve pancreatic ischemia, free fatty acid toxicity, or increased intrapancreatic pressure
• Associated with familial lipoprotein lipase deficiency, genetic hyperlipoproteinemias, uncontrolled diabetes

Medications and toxins

• Immunosuppressants: Azathioprine, 6-mercaptopurine
• Antimicrobials: Sulfonamides, tetracyclines, fluoroquinolones, valproic acid
• Diuretics: Thiazides, loop diuretics
• Chemotherapy agents: Corticosteroids in some cases
• Scorpion and spider envenomation, organophosphate poisoning

Post-ERCP pancreatitis

• Occurs in 3-5% of all ERCP procedures; up to 25% of high-risk patients
• Mechanical trauma to sphincter of Oddi, intraductal contrast injection, or papillotomy-related edema
• Risk factors: Sphincter of Oddi dysfunction, female gender, young age, post-surgical anatomy

Genetic causes (familial pancreatitis)

• PRSS1 mutations (cationic trypsinogen): Most common genetic variant; autosomal dominant inheritance with ~80% penetrance
• CFTR mutations (cystic fibrosis transmembrane conductance regulator): Predispose to both acute and chronic pancreatitis
• CASR mutations (calcium-sensing receptor): Mild hypercalcemia-associated pancreatitis

Metabolic and endocrine disorders

• Hypercalcemia (hyperparathyroidism, vitamin D intoxication, granulomatous diseases): Elevated calcium increases risk through uncertain mechanism
• Hemophagocytic lymphohistiocytosis (HLH): Can present with acute pancreatitis
• Hypoparathyroidism and related calcium metabolism disorders

Infectious triggers

• Viral: Mumps, measles, coxsackievirus B, hepatitis A and B, CMV, HIV, COVID-19
• Bacterial: Mycoplasma, leptospirosis, brucellosis
• Parasitic: Ascaris lumbricoides, Toxoplasma

Autoimmune pancreatitis (AIP)

• Type 1 IgG4-related disease: Segmental or diffuse pancreatic involvement with fibrosis; associated with other IgG4-related diseases
• Type 2: ANCA-associated, primarily affects young people; worse prognosis

Anatomic abnormalities

• Sphincter of Oddi dysfunction: Fibrosis or dysfunction impedes enzyme secretion
• Pancreas divisum: Incomplete fusion of dorsal and ventral pancreas; small ventral duct may cause relative obstruction
• Pancreatic or biliary malignancy obstructing ductal flow

Idiopathic pancreatitis

• 10-15% of acute pancreatitis cases lack identifiable cause; some have undetected CFTR or genetic mutations

Chronic Pancreatitis

Chronic alcohol consumption (70% of CP in Western countries)

• Dose-dependent risk; threshold typically ≥100 g ethanol daily for 10+ years
• Mechanism: Oxidative stress, protein precipitation, triglyceride elevation, stellate cell activation
• Women at higher risk than men at lower absolute alcohol doses (5-6 drinks/day vs. 8 drinks/day)

Recurrent acute pancreatitis

• Multiple episodes of AP, regardless of initial cause, can progress to CP
• Particularly associated with genetic predisposition (PRSS1, CFTR, CASR mutations)
• Idiopathic recurrent AP carries significant risk of progression to chronic disease

Autoimmune pancreatitis (AIP)

• Type 1 IgG4-related disease: 90% progress to chronic pancreatitis features; associated with IgG4-related disease affecting other organs (cholangitis, gastritis)
• Type 2 ANCA-associated variant: Poor prognosis, rapid progression

Biliary obstruction (obstructive chronic pancreatitis)

• Persistent ductal obstruction from stones, strictures, or malignancy
• Much less common cause than in acute disease; requires prolonged obstruction

Cystic fibrosis (CFTR mutations)

• Thick, viscous pancreatic secretions due to impaired chloride and fluid secretion
• Early pancreatic involvement with fat malabsorption, exocrine insufficiency, and predisposition to both AP and CP

Genetic mutations (5-10% of CP)

• PRSS1 mutations: Hereditary pancreatitis; autosomal dominant with incomplete penetrance
• CFTR mutations: Can cause CP independent of classic cystic fibrosis phenotype
• CASR mutations, SPINK1 mutations (serine protease inhibitor Kazal type 1): Rare but important

Smoking

• Independent risk factor; synergistic with alcohol
• Increases oxidative stress and fibrosis progression

Idiopathic chronic pancreatitis

• 10-30% of CP cases; may include undetected genetic mutations or CFTR variants

Metabolic disorders

• Hypertriglyceridemia, hyperparathyroidism, hemochromatosis (iron deposition in pancreas)

Autoimmune overlap and other inflammatory conditions

• Overlap with inflammatory bowel disease
• Systemic lupus erythematosus-associated pancreatitis

Pancreatic Ductal Adenocarcinoma

Chronic pancreatitis

• Significantly increases PDAC risk (5-10 fold); risk correlates with duration and severity
• Common precursor lesions (PanIN dysplasia) found in majority of chronic pancreatitis cases
• Chronic inflammation, oxidative stress, and stellate cell activation create tumor-promoting environment

Hereditary cancer syndromes

• Familial adenomatous polyposis (FAP, APC mutation): 40-fold increased risk
• Lynch syndrome (mismatch repair gene deficiency): 2-4 fold increased risk
• Hereditary breast and ovarian cancer (BRCA1/BRCA2 mutations): 2-4 fold increased risk; BRCA2 mutations carry higher relative risk
• Peutz-Jeghers syndrome (STK11/LKB1 mutation): Up to 100-fold increased risk
• Familial atypical multiple mole and melanoma (FAMMM, CDKN2A mutation): 13-22 fold increased risk
• Hereditary pancreatitis (PRSS1 mutations): 50-70 fold increased lifetime risk

Smoking

• 2-5 fold increased risk; dose-dependent relationship
• Synergistic with other risk factors (alcohol, pancreatitis)

Diabetes mellitus

• Type 2 diabetes increases risk 1.5-2 fold
• Long-standing (>5 years) diabetes conveys higher risk
• Bidirectional relationship: new-onset diabetes in elderly patient can be paraneoplastic sign

Obesity and metabolic syndrome

• Modest increased risk (1.2-1.5 fold)
• Chronic inflammation and insulin resistance implicated
• Risk greater for postmenopausal women

Alcohol consumption

• Long-term heavy use increases risk; synergistic with smoking
• Associated chronic pancreatitis mediates much of the risk

Hereditary pancreatitis

• 50-70 fold lifetime risk of PDAC in PRSS1 mutation carriers
• Median age of PDAC onset ~55 years (vs. ~70 years in sporadic disease)
• Requires intensified surveillance

Hepatitis B and C

• Modest increased risk; mechanisms unclear

ABO blood group

• Non-O blood group associated with increased risk
• Genetic polymorphisms affecting inflammation and carcinogen metabolism implicated

Prior history of cholecystectomy

• Conflicting data; some studies suggest modest increased risk

Age

• Incidence peaks in 7th-8th decades of life
• Median age at diagnosis ~71 years
• Increasingly recognized in younger patients with familial/genetic predisposition

Male gender

• Slight male predominance (1.3:1)

Acute Pancreatitis

Cardinal symptom: epigastric pain

• Sudden onset, severe intensity (often 8-10/10), constant (not colicky) pain
• Epigastric location with radiation to left upper quadrant or back (distinguishes from biliary colic)
• Typically persists for hours to days (contrasts with biliary colic, which is intermittent)
• Worse in supine position; often relieved by sitting forward or flexing knees
• Aggravated by eating (triglyceride-rich meals particularly problematic)

Associated gastrointestinal symptoms

• Nausea and persistent vomiting (consequence of gastric dilation and ileus)
• Abdominal distension from paralytic ileus
• Hiccups or gagging (diaphragmatic irritation)

Physical examination findings

Acute pancreatitis — the revised Atlanta classification requires 2 of 3

• Characteristic pain: acute epigastric pain radiating to the back, as described above.
• Lipase (or amylase) ≥3× the upper limit of normal: lipase is the preferred first test — it is more sensitive and specific for pancreatic acinar injury and stays elevated for days after amylase has normalized. The magnitude of enzyme elevation does not correlate with severity and should never be trended to gauge prognosis.
• Cross-sectional imaging findings: needed only when the first two criteria are not both met.

Supporting workup (American College of Gastroenterology guidance)

• Transabdominal right-upper-quadrant ultrasound in every patient: the single best next step after diagnosis, because gallstones are the leading etiology and their presence changes management.
• ALT elevation (roughly threefold or more) has high positive predictive value for a biliary cause; check triglycerides and calcium when stones and alcohol are absent.
• Contrast-enhanced CT is not needed at presentation: necrosis takes time to declare itself, so imaging obtained in the first ~72 hours underestimates it. Reserve CT for diagnostic uncertainty or clinical deterioration.

Severity stratification

• Atlanta severity tiers: mild (no organ failure, no local complications), moderately severe (transient organ failure <48 h or local complications), severe (persistent organ failure >48 h).
• Named scores: Ranson criteria (requires 48 h to complete), APACHE II, and BISAP (BUN >25 mg/dL, impaired mental status, SIRS, age >60, pleural effusion). Rising BUN and hemoconcentration are the most useful bedside predictors of severe disease.

Chronic pancreatitis

• Amylase and lipase are often normal — burned-out parenchyma cannot release enzyme.
• CT showing pancreatic calcifications, and MRCP/ERCP showing alternating ductal dilation and stricture (chain of lakes), are diagnostic; EUS is the most sensitive early modality.
• Reduced fecal elastase-1 documents exocrine insufficiency.

Pancreatic adenocarcinoma (NCCN)

• Pancreas-protocol multiphase contrast CT is the diagnostic and staging study; it defines resectable, borderline resectable, locally advanced, and metastatic disease.
• EUS-guided fine-needle biopsy obtains tissue when neoadjuvant therapy or diagnostic doubt requires it.
• CA 19-9 is for prognosis and treatment monitoring, not screening or diagnosis; it is falsely elevated in cholestasis and undetectable in Lewis antigen–negative patients.

Immediate management of acute pancreatitis (ACG and AGA)

• Goal-directed intravenous crystalloid, lactated Ringer's preferred: replaces third-spaced volume and preserves pancreatic microcirculation; LR is favored over normal saline (less hyperchloremic acidosis, possible anti-inflammatory benefit). Titrate to urine output, heart rate, and falling BUN/hematocrit — indiscriminate high-volume resuscitation causes fluid overload and is no longer endorsed.
• Analgesia with opioids: e.g., hydromorphone or fentanyl; no evidence that opioids worsen sphincter of Oddi tone clinically.
• Early enteral nutrition: oral low-fat feeding within 24–48 hours as tolerated maintains gut mucosal barrier and reduces bacterial translocation; nasogastric/nasojejunal tube feeding if oral intake fails. Prolonged NPO and routine TPN are contraindicated.

Etiology-specific escalation

• Urgent ERCP with sphincterotomy (within ~24 h): only for gallstone pancreatitis with concurrent cholangitis or persistent biliary obstruction — not for gallstone pancreatitis alone.
• Same-admission cholecystectomy for mild biliary pancreatitis prevents recurrence.
• Hypertriglyceridemic pancreatitis: insulin infusion (activates lipoprotein lipase) ± apheresis acutely; fibrate (fenofibrate) long term.
• Antibiotics only for proven or strongly suspected infected necrosis — a carbapenem such as meropenem penetrates necrotic pancreas. Prophylactic antibiotics for sterile necrosis are contraindicated.
• Symptomatic walled-off necrosis: delay intervention ~4 weeks for wall maturation, then a step-up approach — endoscopic transmural or percutaneous drainage before minimally invasive necrosectomy; open necrosectomy is last resort.

Chronic pancreatitis

• Alcohol and tobacco cessation first, then non-opioid analgesics; pancreatic enzyme replacement (lipase-containing pancrelipase) with acid suppression for steatorrhea, plus fat-soluble vitamin repletion.
• **Endoscopic stone/stricture therapy or lateral pancreaticojejunostomy (Puestow)** for a dilated obstructed duct; celiac plexus block for refractory pain.

Pancreatic adenocarcinoma (NCCN)

• Resectable head lesions: pancreaticoduodenectomy (Whipple); distal pancreatectomy with splenectomy for body/tail — followed by adjuvant multi-agent chemotherapy (modified FOLFIRINOX in fit patients, gemcitabine-based otherwise).
• Borderline resectable/locally advanced: neoadjuvant chemotherapy ± radiation.
• Metastatic: FOLFIRINOX for good performance status, gemcitabine plus nab-paclitaxel otherwise; germline testing is recommended for all patients, with PARP inhibitor maintenance for *BRCA*-mutated disease.
• Palliation: endoscopic biliary stenting for obstructive jaundice, celiac plexus neurolysis for pain.

Local complications of pancreatitis

• Pseudocyst: peripancreatic fluid collection walled off by granulation/fibrous tissue after ~4 weeks and lacking an epithelial lining (hence "pseudo"). Suggested by persistent pain, early satiety, or a persistently elevated amylase; drain only if symptomatic or infected.
• Infected necrosis — emergency: gas bubbles within necrosis on CT, or clinical deterioration with fever and leukocytosis after the first week. Carries the highest mortality of any local complication; requires carbapenem therapy and step-up drainage.
• Splenic vein thrombosis: peripancreatic inflammation propagates into the vein, producing isolated gastric varices with a normal liver and normal portal pressures; bleeding is treated with splenectomy.
• Pseudoaneurysm (splenic artery or gastroduodenal artery) — emergency: enzymatic erosion of the arterial wall, signaled by sudden GI or intra-abdominal hemorrhage and a falling hematocrit; treated by angiographic embolization.
• Pancreatic ascites/fistula: ductal disruption leaks enzyme-rich fluid, giving ascitic fluid with markedly elevated amylase.

Systemic complications

• ARDS — emergency: circulating phospholipase A2 degrades surfactant, producing hypoxemia and bilateral infiltrates 2–3 days in.
• Hypocalcemia: released lipase generates free fatty acids that chelate calcium as insoluble soaps (saponification) in fat necrosis; look for Chvostek and Trousseau signs — a marker of severity in Ranson scoring.
• Distributive/hypovolemic shock, AKI, and DIC from SIRS and massive third-spacing; abdominal compartment syndrome is a treatment-related hazard of over-resuscitation.

Chronic pancreatitis sequelae

• Exocrine insufficiency: steatorrhea and fat-soluble vitamin (A, D, E, K) deficiency appear only after most acinar mass is lost.
• Pancreatogenic (type 3c) diabetes: loss of both insulin and glucagon makes glycemic control brittle and hypoglycemia-prone.
• Common bile duct stricture and markedly increased risk of adenocarcinoma.

Malignancy- and procedure-related

• Trousseau syndrome (migratory thrombophlebitis) from tumor-derived procoagulants; gastric outlet obstruction, malignant ascites, and cachexia.
• Post-Whipple: delayed gastric emptying, pancreatic anastomotic leak/fistula, and exocrine insufficiency.
• Post-ERCP pancreatitis: mitigated by periprocedural rectal NSAID (indomethacin) and pancreatic duct stenting in high-risk patients.

• Lipase ≥3× ULN plus classic pain closes the diagnosis — no imaging needed. The common distractor is ordering a CT scan first; the single best next step after diagnosing acute pancreatitis is a right-upper-quadrant ultrasound for gallstones.
• Enzyme magnitude ≠ severity. A lipase of 4,000 predicts nothing. Severity is judged by organ failure (Atlanta), rising BUN, hemoconcentration, and scores such as Ranson, APACHE II, and BISAP.
• **Hypocalcemia with *Chvostek*/*Trousseau* signs in pancreatitis** is the classic saponification question: lipase-liberated free fatty acids chelate calcium in fat necrosis. Do not attribute it to hypoparathyroidism.
• ***Cullen* (periumbilical) and Grey Turner (flank) ecchymoses** signal retroperitoneal hemorrhage in severe necrotizing disease — buzzwords, not sensitive signs.
• Isolated gastric varices with a normal liver = splenic vein thrombosis from adjacent pancreatic inflammation or tumor; the answer is splenectomy, not a TIPS.
• **Painless obstructive jaundice + palpable non-tender gallbladder (Courvoisier) + new-onset diabetes in an older adult = pancreatic head adenocarcinoma** until proven otherwise. Trousseau migratory thrombophlebitis is the association examiners love.
• CA 19-9 is never a screening or diagnostic test (USPSTF recommends against screening asymptomatic adults for pancreatic cancer); it monitors treatment response and recurrence, is falsely raised by cholestasis, and is absent in Lewis-negative patients. KRAS is the earliest and most frequent mutation; SMAD4/DPC4 loss is the classic tumor-suppressor association.
• Two management traps: prophylactic antibiotics for sterile necrosis are not indicated (only for infected necrosis), and urgent ERCP is reserved for gallstone pancreatitis with cholangitis or persistent obstruction — otherwise the answer is same-admission cholecystectomy. Likewise, early enteral feeding beats prolonged NPO with TPN.